Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly s Pleasant Prairie facility expansion gets final approval, paving the way for a 3 billion Kenosha County investment ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...